Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer

Zheng Ao, Sanket H. Shah, Leah M. Machlin, Ritesh Parajuli, Philip C. Miller, Siddarth Rawal, Anthony J. Williams, Richard J Cote, Marc E Lippman, Ram Datar, Dorraya El-Ashry

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Metastasis is facilitated by cancer-associated fibroblasts (CAF) in the tumor microenvironment through mechanisms yet to be elucidated. In this study, we used a size-based microfilter technology developed by our group to examine whether circulating CAF identified by FAP and α-SMA co-expression (cCAF) could be distinguished in the peripheral blood of patients with metastatic breast cancer. In a pilot study of patients with breast cancer, we detected the presence of cCAFs in 30/34 (88%) patients with metastatic disease (MET group) and in 3/13 (23%) patients with localized breast cancer (LOC group) with long-term disease-free survival. No cCAFs as defined were detected in healthy donors. Further, both cCAF and circulating tumor cells (CTC) were significantly greater in the MET group compared with the LOC group. Thus, the presence of cCAF was associated with clinical metastasis, suggesting that cCAF may complement CTC as a clinically relevant biomarker in metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)4681-4687
Number of pages7
JournalCancer Research
Volume75
Issue number22
DOIs
StatePublished - Nov 15 2015

Fingerprint

Breast Neoplasms
Circulating Neoplastic Cells
Neoplasm Metastasis
Tumor Microenvironment
Disease-Free Survival
Biomarkers
Tissue Donors
Technology
Cancer-Associated Fibroblasts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ao, Z., Shah, S. H., Machlin, L. M., Parajuli, R., Miller, P. C., Rawal, S., ... El-Ashry, D. (2015). Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Research, 75(22), 4681-4687. https://doi.org/10.1158/0008-5472.CAN-15-1633

Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. / Ao, Zheng; Shah, Sanket H.; Machlin, Leah M.; Parajuli, Ritesh; Miller, Philip C.; Rawal, Siddarth; Williams, Anthony J.; Cote, Richard J; Lippman, Marc E; Datar, Ram; El-Ashry, Dorraya.

In: Cancer Research, Vol. 75, No. 22, 15.11.2015, p. 4681-4687.

Research output: Contribution to journalArticle

Ao, Z, Shah, SH, Machlin, LM, Parajuli, R, Miller, PC, Rawal, S, Williams, AJ, Cote, RJ, Lippman, ME, Datar, R & El-Ashry, D 2015, 'Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer', Cancer Research, vol. 75, no. 22, pp. 4681-4687. https://doi.org/10.1158/0008-5472.CAN-15-1633
Ao, Zheng ; Shah, Sanket H. ; Machlin, Leah M. ; Parajuli, Ritesh ; Miller, Philip C. ; Rawal, Siddarth ; Williams, Anthony J. ; Cote, Richard J ; Lippman, Marc E ; Datar, Ram ; El-Ashry, Dorraya. / Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. In: Cancer Research. 2015 ; Vol. 75, No. 22. pp. 4681-4687.
@article{32bb9e59f097451d8fd8b0ee2c1fb91c,
title = "Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer",
abstract = "Metastasis is facilitated by cancer-associated fibroblasts (CAF) in the tumor microenvironment through mechanisms yet to be elucidated. In this study, we used a size-based microfilter technology developed by our group to examine whether circulating CAF identified by FAP and α-SMA co-expression (cCAF) could be distinguished in the peripheral blood of patients with metastatic breast cancer. In a pilot study of patients with breast cancer, we detected the presence of cCAFs in 30/34 (88{\%}) patients with metastatic disease (MET group) and in 3/13 (23{\%}) patients with localized breast cancer (LOC group) with long-term disease-free survival. No cCAFs as defined were detected in healthy donors. Further, both cCAF and circulating tumor cells (CTC) were significantly greater in the MET group compared with the LOC group. Thus, the presence of cCAF was associated with clinical metastasis, suggesting that cCAF may complement CTC as a clinically relevant biomarker in metastatic breast cancer.",
author = "Zheng Ao and Shah, {Sanket H.} and Machlin, {Leah M.} and Ritesh Parajuli and Miller, {Philip C.} and Siddarth Rawal and Williams, {Anthony J.} and Cote, {Richard J} and Lippman, {Marc E} and Ram Datar and Dorraya El-Ashry",
year = "2015",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-15-1633",
language = "English (US)",
volume = "75",
pages = "4681--4687",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer

AU - Ao, Zheng

AU - Shah, Sanket H.

AU - Machlin, Leah M.

AU - Parajuli, Ritesh

AU - Miller, Philip C.

AU - Rawal, Siddarth

AU - Williams, Anthony J.

AU - Cote, Richard J

AU - Lippman, Marc E

AU - Datar, Ram

AU - El-Ashry, Dorraya

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Metastasis is facilitated by cancer-associated fibroblasts (CAF) in the tumor microenvironment through mechanisms yet to be elucidated. In this study, we used a size-based microfilter technology developed by our group to examine whether circulating CAF identified by FAP and α-SMA co-expression (cCAF) could be distinguished in the peripheral blood of patients with metastatic breast cancer. In a pilot study of patients with breast cancer, we detected the presence of cCAFs in 30/34 (88%) patients with metastatic disease (MET group) and in 3/13 (23%) patients with localized breast cancer (LOC group) with long-term disease-free survival. No cCAFs as defined were detected in healthy donors. Further, both cCAF and circulating tumor cells (CTC) were significantly greater in the MET group compared with the LOC group. Thus, the presence of cCAF was associated with clinical metastasis, suggesting that cCAF may complement CTC as a clinically relevant biomarker in metastatic breast cancer.

AB - Metastasis is facilitated by cancer-associated fibroblasts (CAF) in the tumor microenvironment through mechanisms yet to be elucidated. In this study, we used a size-based microfilter technology developed by our group to examine whether circulating CAF identified by FAP and α-SMA co-expression (cCAF) could be distinguished in the peripheral blood of patients with metastatic breast cancer. In a pilot study of patients with breast cancer, we detected the presence of cCAFs in 30/34 (88%) patients with metastatic disease (MET group) and in 3/13 (23%) patients with localized breast cancer (LOC group) with long-term disease-free survival. No cCAFs as defined were detected in healthy donors. Further, both cCAF and circulating tumor cells (CTC) were significantly greater in the MET group compared with the LOC group. Thus, the presence of cCAF was associated with clinical metastasis, suggesting that cCAF may complement CTC as a clinically relevant biomarker in metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84954486898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954486898&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1633

DO - 10.1158/0008-5472.CAN-15-1633

M3 - Article

VL - 75

SP - 4681

EP - 4687

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -